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Background: Malignant diseases are responsible of approximately 13% of all deaths each year in the world. Natural
products represent a valuable source for the development of novel anticancer drugs. The present study was aimed
at evaluating the cytotoxicity of a naphtyl butanone isolated from the leaves of Guiera senegalensis, guieranone A
(GA).
Results: The results indicated that GA was active on 91.67% of the 12 tested cancer cell lines, the IC50 values below
4 μg/ml being recorded on 83.33% of them. In addition, the IC50 values obtained on human lymphoblastic
leukemia CCRF-CEM (0.73 μg/ml) and its resistant subline CEM/ADR5000 (1.01 μg/ml) and on lung adenocarcinoma
A549 (0.72 μg/ml) cell lines were closer or lower than that of doxorubicin. Interestingly, low cytotoxicity to normal
hepatocyte, AML12 cell line was observed. GA showed anti-angiogenic activity with up to 51.9% inhibition of the
growth of blood capillaries on the chorioallantoic membrane of quail embryo. Its also induced apotosis and cell
cycle arrest. Ingenuity Pathway Analysis identified several pathways in CCRF-CEM cells and functional group of
genes regulated upon GA treatment (P< 0.05), the Cell Cycle: G2/M DNA Damage Checkpoint Regulation and ATM
Signaling pathways being amongst the four most involved functional groups.
Conclusion: The overall results of this work provide evidence of the cytotoxic potential of GA and supportive data
for its possible use in cancer chemotherapy.
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Malignant diseases are responsible of approximately 13%
of all deaths each year in the world. About 12.7 million
cancer cases and 7.6 million cancer deaths are estimated
to have occurred in 2008; of these, 56% of the cases and
64% of the deaths occurred in the economically develop-
ing world [1]. Breast cancer is the most frequently
diagnosed cancer and the leading cause of cancer death
among females, accounting for 23% of the total cancer
cases and 14% of the cancer deaths; Lung cancer is the
leading cancer site in males, comprising 17% of the total
new cancer cases and 23% of the total cancer deaths [1].
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reproduction in any medium, provided the orthe developed world and the second leading cause of
death in the developing world [1]. In 2000, leukemia
represented about 3% of the almost seven million deaths
due to cancer that year, and about 0.35% of all deaths
from any cause [2]. Natural products represent a valu-
able source for the development of novel anticancer
drugs. The present study was focused on the cytotoxic
potential of a naphtyl butanone, a major component of
the leaves of Guiera senegalensis, GA. This compound
previously showed good antifungal activity against
Cladosporium cucumerinum [3], strong antiplasmodial
activity and high cytotoxicity towards two cancer cell
lines: HCT-116 colon carcinoma and THP-1 human
acute monocytic leukemia [4]. Interestingly, the
complete chemical synthesis of GA was reported [5].
Therefore, we undertook the present work to highlight
the anticancer potential of this compound and its pos-
sible effects on cell cycle distribution, apoptosis,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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model. The study was also extended to the search of the
anti-angiogenic potency of GA.
Methods
Chemical for cytotoxicity assay
Doxorubicin (Sigma-Aldrich, Schnelldorf, Germany) was
used as a positive (cytotoxic) control. Captopril (Sigma-
Aldrich) was used as positive anti-angiogenic control.
GA was isolated from the methanol extract from the
leaves of Guiera senegalensis; The leaves of the plant
were collected in Mount Kala (Centre Region of Camer-
oon, Africa) in May 2008. The plant was identified at the
Cameroon National Hebarium (Yaounde) were a vou-
cher specimen was deposited. The air-dried and pow-
dered leaves (1.5 kg) were soaked in 6 L of methanol for
48 h, at room temperature. The methanol extract was
concentrated under reduced pressure to give 120 g of a
Green-dark residue that constituted the crude extract
(GSL). Part of this extract (100 g) was submitted to
repeated silica gel 60 (0.04–0.063 mm, 200 g) and thin
layer chromatography (TLC) to afforded GA C18H20O5
(light yellow crystals; 48 mg; m/z 316; m.p. 99–101°C)
[3,6] (Detailed isolation and general experimental proce-
dures are available as Supporting information).
Cell lines treatment
A panel of fourteen cancer cell lines including human
lymphoblastic CCRF-CEM leukemia cells and their
multidrug-resistant subline, CEM/ADR5000, MiaPaCa-2
and Capan-1 pancreatic adenocarninoma cells, MCF-7
breast adenocarcinoma cells, SW-680 colon carcinoma
cells, 786–0 renal carcinoma cells, U87MG glioblastoma
cells, A549 lung adenocarcinoma cells, Caski and HeLa
cervical carcinoma cells, Colo-38 skin melanoma cells,
as well as AML12 normal hepatocytes were used. Cell
lines were obtained from different sources: Prof. Axel
Sauerbrey, University of Jena, Jena, Germany (CCRF-
CEM, CEM/ADR5000), Dr. Jörg Hoheisel, German
Cancer Research Center, Heidelberg, Germany (Mia-
PaCa-2, Capan-1, MCF-7, SW-680), Tumor Bank,
German Cancer Research Center, Heidelberg, Germany
(786–0, U87MG, A549, Caski, HeLa, Colo-38), Ameri-
can Type Culture Collection,USA (AML12).
All cell lines were maintained in RPMI 1640 contain-
ing 100 units/ml penicillin and 100 μg/ml streptomycin
and supplemented with heat-inactivated 10% fetal bovine
serum (FBS). All cultured cells were maintained in a hu-
midified incubator at 37°C with 5% CO2. Multidrug
resistance of CEM/ADR5000 was maintained by apply-
ing 5000 ng/ml Doxorubicin every other cell passage.
Doxorubicin (Sigma-Aldrich, Schnelldorf, Germany) was
used as a positive (cytotoxic) control. The concentration
of DMSO was kept at or below 0.1% in all experiments.Resazurin cell growth inhibition assay
Alamar Blue or Resazurin (Promega, Mannheim,
Germany) reduction assay [7] was used to assess the
cytotoxicity of the studied samples. Doxorubicin was
used as positive control. Each assay was done at least
three times, with two replicate each. The viability after
48 h was compared based on a comparison with un-
treated cells. IC50 (on cancer cells) or EC50 (on AML12
cells) values were the concentration of sample required
to inhibit 50% of the cell proliferation and was calculated
from a calibration curve by a linear regression [8], using
Microsoft Excel (The detailed Resazurin assay is avail-
able in Supporting information).
Flow cytometry for cell cycle analysis and detection of
apoptotic cells
Leukemia CCRF-CEM cells treated with GA or DMSO
(solvent control) for 24 to 72 h were fixed with ethanol
95% and washed with cold, phosphate-buffered saline
(PBS; Invitrogen) and then resuspended in 150 μl hypo-
tonic fluorochrome solution (50 μg/ml propidium iodide,
10 μg/ml RNAse A in PBS). The cells were incubated in
the dark at 4°C overnight before flow-cytometry analysis
was performed. The propidium iodide fluorescence of in-
dividual nuclei was measured using a FACS-Calibur
cytometer (BD Biosciences, Heidelberg, Germany). Data
were analyzed with the CellQuess Pro V5.2.1 software (BD
Biosciences). For each condition, at least three independ-
ent experiments were performed.
Caspase-glo 3/7 assay
The influence of GA on caspase 3/7 activity in CCRF-
CEM leukemia cells was detected using Caspase-Glo 3/7
Assay kit (Promega). Cells cultured in RPMI were seeded
in 96-well plates and treated with the sample (2 × IC50;
IC50; ½ × IC50) or DMSO (solvent control). After 24 h
treatment, 100 μl of caspase 3/7 reagent were added to
each well, mixed and incubated for 1 h at room
temperature. Luminescence was measured using well
Infinite M2000 Pro™ instrument (Tecan). Caspase 3/7
activity was expressed as percentage of the untreated
control.
Detection of angiogenesis in vivo by cultivation of quail
eggs
The quail eggs were purchased from Wachtelzucht Anne
Klein, Steinhagen, Germany. The embryos were cultured
according to the method described by Wittmann et al.
[9]. GA and captopril (as positive control drug) were
tested for their anti-angiogenic effects at 20 μg/ml, using
chicken chorioallantoic membrane assay (CAM assay)
method as described by D’Arcy and Howard [10], with
modifications according to Marchesan et al. [11]. The
percentage inhibition of vascularization was calculated
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tests are available in Supporting information).
mRNA-based microarray expression profiling
RNA isolation and analysis
Total RNA from CCRF-CEM cells was isolated using
RNeasy Kit from Qiagen (Hilden, Germany) according
to the manufacture’s instruction. RNA was resuspended/
eluted in TE/water. The quality of total RNA was
checked by gel analysis using the total RNA Nano chip
assay on an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies GmbH, Berlin, Germany). Only samples with RNA
index values greater than 8.5 were selected for expres-
sion profiling. RNA concentrations were determined
using the NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE).
Probe labeling and illumina sentrix BeadChip array
hybridization
Biotin-labeled cRNA samples for hybridization on Illu-
mina Human Sentrix-HT12 BeadChip arrays (Illumina,
Inc.) were prepared according to Illumina’s recommended
sample labeling procedure based on the modified Eber-
wine protocol [13] (Detailed tests is available in Supportive
information).
Scanning and data analysis
Microarray scanning was done using a Beadstation array
scanner, setting adjusted to a scaling factor of 1 and
PMT settings at 430. Data extraction was done for all
beads individually, and outliers are removed when> 2.5
MAD (median absolute deviation). All remaining data
points are used for the calculation of the mean average
signal for a given probe, and standard deviation for each
probe was calculated.
Data analysis was done by normalization of the signals
using the quantile normalization algorithm without back-
ground subtraction, and differentially regulated genes are
defined by calculating the standard deviation differences
of a given probe in one-by-one comparisons of samples or
groups.
All data is MIAME compliant and the raw data has been
deposited in a MIAME compliant database as detailed on
the MGED Society website http://www.ebi.ac.uk/arrayex-
press/experiments/E-MTAB-731 (Accession number E-
MTAB-731).
Real-time (RT)-PCR
The same RNA samples used for microarray experiment
were also used for RT-PCR experiments. RNA samples
extracted from cells treated with GA or DMSO (solvent
control) were converted to cDNA by reverse transcript-
ase (Invitrogen) using random hexamerprimers. The
cDNAs were quantified by real-time PCR using theSsoFast EvaGreen PCR Kit (Bio-RAD, München,
Germany) and the CFX384TM Real-Time PCR Detection
Systems (Bio-RAD), PCR was done by initial incubation
at 50°C for 10 min, denaturation at 95°C for 5 min and
40 cycles were performed in two steps for each: denatur-
ation at 95°C for 30 s, annealing at 62°C for 40 s. Melt
Curve was performed by cooling from 95°C to 65°C, fol-
lowed by a gradual increase in temperature (0.5°C/5 s)
to 95°C. Expression levels were normalized relative to
the transcription level of G6PD. All samples were run in
triplicate.
Statistical analysis
Statistical analysis of all data was performed using a Stu-
dent’s t-test or Kruskal–Wallis test followed by Dunn’s
post-hoc multiple comparison test (Graph-Pad Prism
5.01; GraphPad Software, Inc., CA, USA). P< 0.05
denoted significance in all cases.
Results
Cytotoxicity
The results of the cytotoxicity of GA on a panel of
cancer cell lines are summarized in Table 1. More
than 50% inhibition of proliferation after 48 h treat-
ment were obtained for eleven of the twelve studied
(91.67%) cancer cell lines, with IC50 values below
20 μg/ml. At the concentration of 20 μg/ml, GA did
not induced the proliferation of up to 50% for colon
SW-680 cell lines as well as for normal AML12 cells
(Table 1).
Anti-angiogenic effect of guieranone A
In the present study, GA showed 51.9% inhibition of
blood capillary growth on the chorioallantoic membrane
of quail eggs (Figure 1). However, the anti-angiogenic ef-
fect of GA was still lower than that of the reference
compound, captopril (76.46% inhibition).
Cell cycle analysis and apoptosis
The flow cytometry data (Figure 2) indicate that GA did
not significantly induce apoptosis in the early phase after
treatment of CRRF-CEM cells (24 h), but that the cells
progressively underwent apoptosis in a time- and dose-
dependent manner (up to 30.19% apoptosis after 72 h at
2 × IC50 treatment), and significant reduction of cells in
G0/G1 phase and cell cycle arrest betwen S and G2/M
phase. This compound also induced low caspase 3/7 ac-
tivity (Additional file 1: Figure S1) in CCRF-CEM cells
after 6 h.
Microarray analysis and signaling pathway profiling
To identify pathways and possible molecular targets
involved in the antitumor effect of GA, CCRF-CEM cells
were then treated with this compound and subjected to
Table 1 Cytotoxicity of Guieranone A and Doxorubicin in various cancer cell lines
















μg/ml μM μg/ml μM
CCRF-CEM 0.73± 0.11 2.31± 0.35 0.62 ± 0.003 1.14 ± 0.005
CEM/ADR5000 1.01± 0.09 (1.38) 3.19± 0.28 >20 (>32.26) >36.8
MiaPaCa-2 3.91± 0.25 12.37 ± 0.79 0.95 ± 0.06 1.75 ± 0.11
Capan-1 9.19 ± 2.29 29.08 ± 7.24 4.06 ± 1.18 7.47 ± 2.17
MCF-7 1.08± 0.32 3.42 ± 0.90 0.59 ± 0.05 1.08 ± 0.09
SW-680 >20 >63.29 0.93 ± 0.09 1.71 ± 0.17
786-0 3.68± 0.54 11.32 ± 1.70 0.60 ± 0.09 1.10 ± 0.17
U87MG 2.46± 0.02 7.78 ± 0.05 0.37 ± 0.08 0.68 ± 0.14
A549 0.72± 0.07 2.28± 0.22 1.69 ± 0.05 3.11 ± 0.09
Colo-38 2.43± 0.75 7.69 ± 1.38 0.81 ± 0.06 1.49 ± 0.11
HeLa 0.51± 0.04 1.61 ± 0.13 0.26 ± 0.02 0.48 ± 0.04
Caski 1.18± 0.11 3.73 ± 0.35 0.58 ± 0.02 1.07 ± 0.04
AML12 (EC50)
* >20 >63.29 >20 >36.8
ac*EC50: effective dose showing 50% inhibition of growth proliferation.
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down-regulated genes out of 227 genes (see Additional file
1: Table S2) upon GA treatment in CCRF-CEM cells are
summarized in Table 2.Figure 1 Effects of Guieranone A (at 20 μg/ml) on the growth of bloo
DMSO (control): Normal growth of blood capillaries on the CAM – no antia
Captopril (76.46% inhibition± 3.6%).The Ingenuity Pathway Analysis (version 6.5) identi-
fied several pathways (Additional file 1: Tables S3 and
S4) and functional group of genes in CCRF-CEM
cells which were regulated upon GA treatmentd capillaries on the chorioallantoic membrane of quail eggs. (A)
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Figure 2 Cell cycle distribution of CCRF-CEM leukemia cells upon Guieranone A treatment. A: control; B: Guieranone A at 2 × IC50 value; C:
Guieranone A at IC50 value; D: Guieranone A at 1/2 × IC50 value; (1); after 24 h; (2); after 48 h; (3); after 72 h.
Kuete et al. Cell Division 2012, 7:16 Page 5 of 12
http://www.celldiv.com/content/7/1/16(significance value of P< 0.05). Amongst the top four
functional groups of genes (Table 3), the Cell Cycle:
G2/M DNA Damage Checkpoint Regulation and ATM
Signaling pathways (Additional file 1: Figure S1) was
directly linked to cancer. CHK1 (Serine/threonine-
protein kinase gene; cell cycle control and particularly
for entry into mitosis) was found to be down-
regulated in these two parthways (Additional file 1:
Figure S5). In addition WEE1 (nuclear kinase gene;
key regulator of cell cycle progression) (Additional file
1: Table S2) is down-regulated in Cell Cycle: G2/M
DNA Damage Checkpoint Regulation following GA
treatment, giving some explanation on the way of cell
death is induced.
The networks representing the four most important
functional group of genes affected by GA treatment
are illustrated in Figures 3 and 4. The two most up-
regulated genes are HSPA6 (heat shock 70 kDa
protein 6) and HIST1H2BD (histone cluster 1, H2bd)
(Table 2, Figure 4A). Further genes of interest which
are up-regulated are FOSB and JUN, HIST1H2BD,
HIST2H2AC, HIST2H2AA4, CD52 (Table 3). Import-
ant down-regulated genes found upon GA treatment
were ACTB and ACTBL3, PGAM1, LOC728188,DHRS2, KPNA2, THOC4, RAB37 and TRAPPC6A,
HNRNPK, LYAR and YBX1, LYAR, YBX1, MYCN,
RUVBL1 (Figure 3 and 4).
Real time RT-PCR
To verify the microarray data with a second independent
method, RT-PCR was exemplarily performed for some
differentially regulated genes (i.e. ACTB, GADD45,
HSP90AB1, LYAR as well as for G6PD as reference). All
results were in accordance with the microarray results
(see Additional file 1: Figure S6).
Discussion
Cytotoxicity
In the US NCI plant screening program, a compound
is generally considered to have in vitro cytotoxic ac-
tivity, if the IC50 value following incubation between
48 and 72 h, is less than 4 μg/ml or 10 μM [14]. In
the present work, the IC50 values below 4 μg/ml were
recorded on 11/14 (75.57%) of the studied cancer
cells, clearly highlighting the good cytotoxicity poten-
tial of GA. In addition, values obtained on CCRF-
CEM (IC50 of 0.73 μg/ml) and its multidrug-resistant
subline, CEM/ADR5000 (1.01 μg/ml), A549 (0.72 μg/
Table 2 Ten most down- or up-regulated genes in CCRF-CEM cells after treatment guieranone A
ID Symbol Description Fold Change
Up-regulated genes
160092 HSPA6 heat shock 70 kDa protein 6 (HSP70B) 11.43
290730 HIST1H2BD histone cluster 1, H2bd 8.00
7160239 FOSB FBJ murine osteosarcoma viral oncogene homolog B 5.39
1820592 HIST2H2AA4 histone cluster 2, H2aa4 4.45
20129 CD52 CD52 molecule 4.16
610451 HIST2H2AA4 histone cluster 2, H2aa4 4.07
6510367 JUN jun oncogene 3.86
6660601 HMOX1 heme oxygenase (decycling) 1 3.64
1500600 RAB37 RAB37, member RAS oncogene family 3.34
6860072 TRAPPC6A trafficking protein particle complex 6A 3.29
Down-regulated genes
2850020 DHRS2 dehydrogenase/reductase (SDR family) member 2 −4.17
3420400 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) −4.18
4230196 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) −4.48
460286 THOC4 THO complex 4 −4.50
4390315 HNRNPA1P2 heterogeneous nuclear ribonucleoprotein A1 pseudogene 2 −4.77
2750719 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 −4.91
4890671 DHRS2 dehydrogenase/reductase (SDR family) member 2 −5.68
4880646 ACTBL3 actin, beta-like 3 −5.70
3940592 PGAM1 phosphoglycerate mutase 1 (brain) −5.76
5270730 ACTB actin, beta −6.50
*Full list of gene in Supplementary Material.
Table 3 Functions associated with the top four group of genes (Figures 3, 4) whose expression was affected by





Top functions* List of all molecules involved
1 50 28 Molecular transport, Protein
trafficking, Cellular assembly
and organization
ACP1, ATP1A1, DDX21, DDX3X, DOK2, ERK1/2, GC-GCR dimer, GNL3,
Histone h3, Histone h4, HNRNPH1, HNRNPK, Importin alpha, Importin beta,
KPNA2, KPNB1, LARP1, LYAR, NCL, NDRG1, NUP62, NUP153, RANBP1, Rnr,
RRP1B, RRS1, SLBP, THOC4, TNFRSF8, TNPO1, TPX2, TSC22D3, TSR1,
WDR12, YBX1
2 50 28 Drug metabolism, endocrine
System development and
function, lipid metabolism
ACTB, Actin, ACTL6A, Akt, alcohol group acceptor phosphotransferase,
CS, FASN, HMGA1, HNRNPL, HSP90AB1, IARS, IKK (complex), IPO4, KEAP1,
Lamin b, MAP3K8, MCM3, MCM4, MORF4L2, MYCN, ORC6L, PDCD6IP,
PSMD6, PTGES3 (includes EG:10728), RNF4, RPL6, RPL7A (includes EG:6130),
RPS24 (includes EG:6229), RUVBL1, SGK1, SLC38A2, SMC3, Thyroid
hormone receptor, TIP60, TUBB
3 47 27 Cell death, cell-to-cell signaling
and interaction, cellular function
and maintenance
14-3-3, ACAT2, AHCY, APIP, ARF3, CD3, CD52, CTPS, FAM83D, FOSB,
FOXO3, GADD45B, HBP1, HNRNPAB, HSPA6, IL10RB, Immunoglobulin, KIF23,
LMNB1, Mapk, Mek, MVP, PDGF BB, Pld, PPHLN1, PPP1R15A, PRDX3, PRKCB,
RBCK1, RGS2, TCR, UTP14A, VIM, YWHAE, YWHAG
4 45 26 Cell cycle, cancer,
gastrointestinal disease
ADAR, APC, CCNA2, CDK1, CDKN3, CHEK1, CNOT7, Cyclin A, DHFR, E2f,
FBXO5, FEN1, H2AFY, ID2, IFI16, KIAA0101, MAD2L1, MAP2K1/2,
methenyltetrahydrofolate cyclohydrolase, methylenetetrahydrofolate
dehydrogenase (NADP), Mre11, MTHFD1, MTHFD2, MTHFD1L, NBN, NUSAP1,
PI3K (complex), PRIM1, Rb, RFC4, TFDP1, TINF2, TYMS, WEE1, XRCC5
*List of all function in Supplementary Material S8. The score is the rounded negative base-ten logarithm of a p-value that measures the likelihood of genes in the
network or functional cluster occuring by chance. A score of 50 means that a cetrain network or cluster has the approximately likelihood of 10-50 of occuring by
random chance.
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Figure 3 Network of differentially regulated genes upon Guieranone A treatment. (A) Molecular transport, protein trafficking, cellular
assembly and organization, (B) Drug metabolism, endocrine system development and function, lipid metabolism. (+): upregulted; (−):
downregulated.
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clearly confirming this statement. Besides, GA was ac-
tive on multidrug-resistant CEM/ADR5000 cells,suggesting that this compound might be useful for
cancer therapy, including tumor cells resistant to
some of the commonly used anticancer drugs. As the
Figure 4 Network of genes of involved (upon guieranone A treatment) in Cell death, cell-to-cell signaling and interaction, cellular
function and maintenance (A), and Cell cycle, cancer, gastrointestinal disease (B). (+): upregulted; (−): downregulated.
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AML12 normal hepatocytes were used to evaluate the
cytotoxicity of GA in normal cells. Interestingly, the
EC50> 20 μg/ml obtained was higher than the values
obtained against most of the cancer cells (Table 1).The overall results of the cytotoxicity assay indicated
that GA might be a promising candidate as new
anticancer drug. Therefore, further studies were con-
ducted to investigate the possible mode of action of
this compound.
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Angiogenesis, the formation of new blood vessels within
a tumor (or many other tissue types) has become a tar-
get of pharmacological research as well as industrial
drug discovery [15]. Compounds with anti-angiogenic
properties are of importance in the treatment and pre-
vention of malignancies as well as other chronic diseases
[16]. Though GA showed less antiangiogenic activity
than captopril, the result obtained indicates that, in
addition to direct cytotoxicity on cancer cells, this com-
pound could also inhibit the proliferation of blood
vessels in vivo, presumably with negative effect on tumor
progression.
Cell cycle analysis and apoptosis
The low induction of apoptosis at the early stage of
CCRF-CEM cells proliferation is in consistence with the
caspase 3/7 activity study (Additional file 1: Figure S1),
as low activation of these apoptosis effectors was noted
upon 6 h. However, higher apoptosis rates were finally
obtained after 72 h with all tested concentrations, show-
ing that apoptotic pathways are involved in the mechan-
ism of GA-induced cell death in CCRF-CEM leukemia
cells. Therefore, in vivo bioavailability and bioactivity
studies are also to be carried out with this compound, as
GA showed promising in vitro activities but induces
apoptosis upon a long time period (72 h).
Microarray analysis and signaling pathway profiling
The cell cycle arrest in CCRF-CEM cells was early
detected after 24 h and the down regulation of important
genes such as CHK1 and WEE1, as reported above might
plays a considerable role. This allegation is strengthened
by the fact that one of the key players in cell cycle regula-
tion such as GADD45 is also up-regulated following GA
treatment (Additional file 1: Figure S1).
HSPA6 (heat shock 70 kDa protein 6) and HIST1H2BD
(histone cluster 1, H2bd) genes were found to be most up-
regulated upon GA treatment. In cooperation with other
chaperones, Hsp70s stabilize preexistent proteins against
aggregation and mediate the folding of newly translated
polypeptides in the cytosol as well as within organelles.
They bind extended peptide segments with a net
hydrophobic character exposed by polypeptides during
translation and membrane translocation, or following
stress-induced damage (http://www.uniprot.org). Interest-
ingly, 70 kDa heat shock protein protects cells from ische-
mia and its expression is increased in consequence to
hypoglycemia [17,18]. In addition, closely connected genes
to HSPA6, HSPA1A and DNAJB2, were found to be up-
regulated in our anaylses. Whereas HSPA1A is coding for
heat shock 70 kDa protein 1A/1B, DNAJB2 has as protein
product cochaperon Hsp40 (DNAJ in bacteria) which is
essential for Hsp70 function [19]. Interesting genes whichare up-regulated included FOSB and JUN. A combined
up-regulation of these genes with Hsp70 mRNA was earl-
ier observed in as stress response to high acceleration
[20]. This finding also confirmed the assumption that GA
might cause hypoxic stress. Through high acceleration an
induction of ischemia can be observed [20]. Furthmore,
dimerization of protein products of FOSB (a FOS family
member) and JUN constitute the transcription factor AP-
1 which is activated by oxidative stress [21]. Surprisingly, a
cofactor of JUN-activated transciption, DDX21, belonged
to one of the most down-regulated genes in our micro-
array analysis [22]. This findings give reason to speculate
that GA might mimic under-supply of oxygen or glucose
and, therefore, leads to apoptosis (see also Figure 2). Very
interesting in the contest of the latter assumption was that
GA inhibited angiogenesis (Figure 1). It would be worth-
while to investigate, whether the vascular endothelial
growth factor (VEGF), its secretion or even the VEGF re-
ceptor are inhibited by GA leading to interrupted VEGF
signaling, as normally VEGF is activated under hypoxic
conditions [23]. Thereby, the fact that we did not observed
any significant change in VEGF mRNA expression (See
Additional file 1: Table S3) does not mean that VEGF sig-
naling was not targeted by GA. VEGF protein expression
can independently vary from corresponding mRNA
amounts in the cell [24].
Certain histone mRNAs were also up-regulated after
treatment with GA [HIST1H2BD, HIST2H2AC,
HIST2H2AA4 (Table 3)]. This observation is surprising,
as levels of histone mRNA usually increase during S-
phase, but decrease back to baseline level between the
S-phase and mitosis [25]. This finding was also con-
firmed by our FACS analyses showing that cells treated
with 1 × IC50 of GA for 72 h were more often arrested in
the S- or G2/M phases than untreated control cells (see
also Figure 2.C2 and D2).
CD52 is a membrane protein which is discussed as tar-
get molecule for leukemia therapy [26]. Alemtuzumab is
an antibody directly targeting CD52 and already
approved for clinical use [27]. In our experiments, the
mRNA of this protein was strongly up-regulated. A
combined treatment of GA with Ametuzumab may pos-
sibly boost the apoptotic effect of both drugs, as GA
might sensitize cells to Alemtuzumab by inducing CD52
expression and activating CD52 downstream mechan-
isms. This speculations merits further experimentation
in the future.
ACTB and ACTBL3 belonged to the most down-
regulated genes. Beta-actin mRNA levels are known to
be disturbed after ischemia [28], which is in line with
our assumption that GA may mimic hypoxia. Another
gene fitting to our hypothesis is PGAM1, which codes
for phosphoglycerate mutase in glycolysis. Another gene
coding for a protein similar to phosphoglycerate mutase
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LOC728188. Down-regulation of glycolysis key mole-
cules accompanied by hypoxic stress may destroy the en-
tire energy production apperture ultimately leading to
cell death. The mis-regulation in glyco-related mechan-
isms was also indicated by down-regulation of DHRS2,
whose encoded protein preferentially binds to glucose
and related sugars [29].
KPNA2 codes for importin alpha. This protein is a key
player in the nuclear transport of macromolecules [30].
Moreover, HNRNPA1P2 is rarely investigated yet, but
seems to be involved to mRNA transport from the nu-
cleus to cytosol (according to UniProt database, www.
uniprot.org). THOC4 encoding a more investigated
mRNA transporter molecule was also significantly
down-regulated. The THOC4 protein is part of the
TREX complex, which specifically associates with spliced
mRNA [31]. THOC4 is especially involved in nuclear ex-
port of Hsp70 transcripts [32].
Interestingly, RAB37 and TRAPPC6A encode also two
proteins which are also involved to transport mechanisms
(www.uniprot.org). They were also mis-regulated in their
transcriptional activity after GA treatment. In summary, it
seems that transport mechanisms are de-regulated as con-
sequence of treatment with this compound.
Recapitulating, GA seems to cause hypoxia and
hypoglycemia as several genes of these functions were
affected. Furthermore, a considerable de-regulation of
several protein- and mRNA-transporter genes was
observed. The latter findings was also confirmed by In-
genuity Pathway Analyses of the microarray data point-
ing to “Molecular Transport” and “Protein Trafficking”
with highest score (Table 3; Figure 3). In contrast, no
molecules belonging to the other hits of Table 3 were
found to be extremely up- or down-regulated.
In the signaling networks of Figures 3 and 4, more key
players become apparent which do not belong to most
mis-regulated genes in our investigation: HNRNPK,
LYAR and YBX1. According to UniProt database,
HNRNPK is involved in RNA processing and splicing.
However, it is interesting from our point of view that it
seems to be important for enhanced proliferation, as
increased levels of HNRNPK mRNA correlates with
increased proliferative activity [33]. LYAR is a gene
involved in development and cell growth regulation and
especially for leukemia cells, as mRNA levels are
increased, but LYAR mRNA is not or only less expressed
in cells of different healthy tissues, e.g. thymus, bone
marrow, liver, heart, brain, kidney or spleen [34]. YBX1
encodes for a protein, YB-1, which is involved in many
mechanisms: proliferation, mRNA processing, DNA re-
pair, transcription, splicing and drug resistence [35]. The
relation of YB-1 to drug resistance is due to its activa-
tion of the multidrug resistance gene, MDR1 [36]. Inaddition, YBX1 expression is also important for deregu-
lation of the oncogene, MYCN [37] (Figure 3B).
MYCN is a prominent transcription factor important for
tumorigenesis and chemotherapy. MYCN mRNA was
found to be over-expressed in human tumor biopsies [38].
Directly correlated to this finding is the down-regulation of
RUVBL1 mRNA (Figure 3B) encoding a protein which
binds to MYC [39]. It is essential for cell proliferation. In
addition, the RUVBL1 protein is associated with the activa-
tion of NuA4 histone acetyltransferase complex, which is
associated to the de-regulated histone mRNAs mentioned
above [40]. Finally, SGK1 up-regulation is very interesting,
as the encoded protein might counteract the cytotoxic ac-
tivity of GA and activate cell survival processes. It deserves
more detailed investigations in the future to elucidate the
connection between KPNA2 and SGK1, as recognition by
importin alpha of Sgk (protein of SGK1 gene) might be ne-
cessary for nuclear import of activated SGK1 [41].
Furthermore, there is another connection between
SGK1 (Figure 3B) and FOXO3A (Figure 4A). FOXO3A is
a pro-apoptotic protein which is regulated by SGK1 [42].
FOXO3A has also an important role as transcription fac-
tor in oxidative stress reponse and cell protection [43].
Its role in cellular response to GA needs further investi-
gations, because the activity of FOXO3A protein is
controlled by phosphorylation, which was not measured
in our mRNA expression profiling approach. Another
prominent member involved in cell death mechanisms is
YWHAG, which codes for 14-3-3 gamma protein [44].
14-3-3 proteins are directly involved in apoptosis and
cell survival regulation by inhibiting BAD and FOXO3A
[45]. In summary, the signaling network shown in
Figure 3B depicts genes related to cell survival.
The overall results of the present investigation
strengthened the cytotoxic potency, the effect on cell
cycle distribution, apoptosis, angiogenesis of Guieranone
A, and consequently give important information for the
future investigation, that could lead to the potential use
of this compound in cancer therapy.Additional file
Additional file 1: Figure S1. Custumized regulated pathways affected
by guieranone A treatment in CCRF-CEM cells (A). (B) Cell cycle: G2/M
DNA damage checkpoint regulation; (C): ATM signaling. Table S2.
Complete list of Signaling pathways with corresponding genes affected
by treatment of CCRF-CEM cells with guieranone A. Table S3. Enzymatic
activity of caspase 3/7 after 6 h treatment of CCRF-CEM cells. The activity
of caspase 3/7 is expressed as percentage % relative to untreated cells.
Figure S4. Top 10 signaling pathways affected by guieranone A
treatment in CCRF-CEM cells. The evaluation of differentially expressed
genes was performed using the Ingenuity Pathway Analysis software.
(List of all pathways in supplemental data 8). Figure S5. Genes down- or
up-regulated in CCRF-CEM cells after treatment guieranone A. Figure S6.
Results of real-time reverse transcriptase PCR analysis. CCRF-CEM cells
were treated with IC50 concentration of guieranone for 24 h,
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Functions associated with the networks for genes whose expression was
affected by treatment with guieranone A.
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